Guggenheim raised the firm’s price target on NewAmsterdam Pharma (NAMS) to $45 from $41 and keeps a Buy rating on the shares. In talks, management expressed confidence in the progress of the Phase 3 CVOT PREVAIL trial and guided to an update by mid-2026 based on continued adjudication of events through at least two years of follow-up, notes the analyst, who currently expects topline data from PREVAIL by early 2027.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NAMS:
- NewAmsterdam Pharma (NAMS): Buy Rating on Strong PREVAIL Momentum, Broad Phase 3 Cardiovascular Program, and Solid Cash Runway
- NewAmsterdam Pharma reports FY25 revenue $22.5M, consensus $23.27M
- NewAmsterdam Pharma announces upcoming milestones
- NewAmsterdam Pharma management to meet with Piper Sandler
- NewAmsterdam Pharma price target raised to $47 from $44 at RBC Capital